INOVIO: Richter-Helm To Support Large-scale Manufacturing Of COVID-19 Vaccine

(RTTNews) - INOVIO (INO) has entered into an agreement with Richter-Helm BioLogics GmbH & Co. KG to support large-scale manufacturing of INOVIO's investigational DNA vaccine INO-4800, which currently is in Phase 1 clinical testing in the U.S. for COVID-19. The agreement is being partly funded by an initial grant of $1.3 million from the Coalition for Epidemic Preparedness Innovations.

INOVIO plans to produce one million doses of INO-4800 by the end of 2020. The company said the additional capacity provided by Richter-Helm will significantly expand manufacturing of the DNA vaccine candidate to meet urgent needs in the midst of the pandemic.

INOVIO has been working with the German contract manufacturer Richter-Helm BioLogics, which manufactures the company's DNA medicine candidate VGX-3100, since 2014.